Marekani - Kiingereza - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - dicyclomine hydrochloride (unii: cq903kqa31) (dicyclomine - unii:4kv4x8if6v) - dicyclomine hydrochloride is indicated for the treatment of patients with functional bowel/irritable bowel syndrome. dicyclomine hydrochloride is contraindicated in infants less than 6 months of age [see use in specific populations (8.4)] , nursing mothers [see use in specific populations (8.3)] , and in patients with: - unstable cardiovascular status in acute hemorrhage - myasthenia gravis [see warnings and precautions (5.4)] - glaucoma [see adverse reactions (6.3) and drug interactions (7.1)] - obstructive uropathy [see warnings and precautions (5.8)] - obstructive disease of the gastrointestinal tract [see warnings and precautions (5.5)] - severe ulcerative colitis [see warnings and precautions (5.7)] - reflux esophagitis pregnancy category b adequate and well-controlled studies have not been conducted with dicyclomine hydrochloride in pregnant women at the recommended doses of 80 to 160 mg/day. however, epidemiologic studies did not show an increased risk of structural malformations among babies born to w

Ubelgiji - Kiingereza - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

b. braun melsungen ag - naloxone hydrochloride dihydrate 0,44 mg/ml - eq. naloxone hydrochloride 0,4 mg/ml - solution for injection/infusion - 0,4 mg/ml - naloxone hydrochloride dihydrate 0.44 mg/ml - naloxone

Ubelgiji - Kiingereza - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

dirinco b.v. - sodium chloride 9 mg/ml - solution for infusion - sodium chloride 9 mg/ml - sodium chloride

Ubelgiji - Kiingereza - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

b. braun melsungen ag - ropivacaine hydrochloride monohydrate 2,116 mg/ml - eq. ropivacaine hydrochloride 2 mg/ml - solution for injection/infusion - 2 mg/ml - ropivacaine hydrochloride monohydrate 2.12 mg/ml - ropivacaine

Ubelgiji - Kiingereza - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

b. braun melsungen ag - ropivacaine hydrochloride monohydrate 2,116 mg/ml - eq. ropivacaine hydrochloride 2 mg/ml - solution for injection/infusion - 2 mg/ml - ropivacaine hydrochloride monohydrate 2.12 mg/ml - ropivacaine

Ubelgiji - Kiingereza - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

b. braun melsungen ag - ropivacaine hydrochloride monohydrate 2,116 mg/ml - eq. ropivacaine hydrochloride 2 mg/ml - solution for injection/infusion - 2 mg/ml - ropivacaine hydrochloride monohydrate 2.116 mg/ml - ropivacaine

Ubelgiji - Kiingereza - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

b. braun melsungen ag - ropivacaine hydrochloride monohydrate 2,116 mg/ml - eq. ropivacaine hydrochloride 2 mg/ml - solution for injection/infusion - 2 mg/ml - ropivacaine hydrochloride monohydrate 2.116 mg/ml - ropivacaine

Ubelgiji - Kiingereza - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

b. braun melsungen ag - ropivacaine hydrochloride monohydrate 2,116 mg/ml - eq. ropivacaine hydrochloride 2 mg/ml - solution for injection/infusion - 2 mg/ml - ropivacaine hydrochloride monohydrate 2.116 mg/ml - ropivacaine

Ubelgiji - Kiingereza - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

b. braun melsungen ag - ropivacaine hydrochloride monohydrate 2,116 mg/ml - eq. ropivacaine hydrochloride 2 mg/ml - solution for injection/infusion - 2 mg/ml - ropivacaine hydrochloride monohydrate 2.116 mg/ml - ropivacaine

Marekani - Kiingereza - NLM (National Library of Medicine)

icu medical inc. - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698) - these solutions are indicated in patients requiring parenteral administration of potassium chloride with minimal carbohydrate calories and sodium chloride. solutions containing potassium chloride are contraindicated in diseases where high potassium levels may be encountered. to open tear outer wrap at notch and remove solution container. if supplemental medication is desired, follow directions below before preparing for administration. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will diminish gradually. to add medication - prepare additive port. - using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. withdraw needle after injecting medication. - the additive port may be protected by covering with an additive cap. - mix container contents thoroughly. preparation for administration (use aseptic technique) - close flow control clamp of administration set. - remove cover from outlet port at bottom of container. - insert piercing pin of administration set into port with a twisting motion until the set is firmly seated. note: see full directions on administration set carton. - suspend container from hanger. - squeeze and release drip chamber to establish proper fluid level in chamber. - open flow control clamp and clear air from set. close clamp. - attach set to venipuncture device. if device is not indwelling, prime and make venipuncture. - regulate rate of administration with flow control clamp. warning: do not use flexible container in series connections.